SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-078145
Filing Date
2023-09-21
Accepted
2023-09-21 08:05:09
Documents
15
Period of Report
2023-09-21
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea185533-8k_jasperthera.htm   iXBRL 8-K 36657
2 PRESS RELEASE, DATED SEPTEMBER 21, 2023 ea185533ex99-1_jasperthera.htm EX-99.1 19121
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4900
  Complete submission text file 0001213900-23-078145.txt   290035

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE jspr-20230921.xsd EX-101.SCH 3928
5 XBRL DEFINITION FILE jspr-20230921_def.xml EX-101.DEF 26833
6 XBRL LABEL FILE jspr-20230921_lab.xml EX-101.LAB 37093
7 XBRL PRESENTATION FILE jspr-20230921_pre.xml EX-101.PRE 25457
9 EXTRACTED XBRL INSTANCE DOCUMENT ea185533-8k_jasperthera_htm.xml XML 5621
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 231267779
SIC: 2836 Biological Products, (No Diagnostic Substances)